ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1994-01-01
- Employees
- 37
- Market Cap
- -
- Website
- https://www.ocata.com
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT03178149
- Locations
- 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸Retinal Consultants of Arizona LTD, Retinal Research Institute, Phoenix, Arizona, United States
🇺🇸Jules Stein Eye Institute, Los Angeles, California, United States
A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
- Conditions
- Macular Degenerative Disease
- Interventions
- Biological: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT03167203
- Locations
- 🇺🇸
Private Practice, Kansas City, Missouri, United States
🇬🇧Site GB44001, London, United Kingdom
A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
- Conditions
- Stargardt's Macular Dystrophy
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT02941991
- Locations
- 🇬🇧
Moorefields Eye Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧Newcastle on Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Biological: Sub-retinal transplantation of MA09-hRPE cellsProcedure: Sham Surgery
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Registration Number
- NCT02563782
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02463344
- Locations
- 🇺🇸
Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Mass Eye and Ear, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next